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To the Editor, 
 
We read with interest the recent data from the FULFIL trial which showed that 
for both co-primary end points, triple therapy comprising inhaled corticosteroid 
with long acting beta-agonist and muscarinic antagonist (ICS/LABA/LAMA) 
was superior to twice daily dual therapy (ICS/LABA) after 24 weeks in patients 
with COPD (1), confirming the known benefits of dual verses single long 
acting bronchodilator therapy(2). It was nonetheless impressive that for trough 
FEV1 at 24 weeks, the mean difference of 171ml was not only statistically 
significant but also exceeded the minimal clinical important difference (MCID) 
of 100ml(3), suggesting that the impact of single inhaler triple therapy was 
clinically relevant. The same was not however true for SGRQ score where the 
mean difference of 2.2, while statistically significant, was less than the MCID 
of 4.0. Nonetheless there were 35% significantly fewer exacerbations at the 
same time point. A real life observational study with time dependent analysis 
in 2853 patients with COPD over 4.65 years showed a 29% significant 
reduction in exacerbations requiring oral corticosteroids and 15% significantly 
fewer hospital admissions conferred by taking once daily tiotropium in addition 
to twice daily ICS/LABA as separate inhalers (4). Moreover such triple therapy 
was associated with 35% significantly lower all cause mortality. The question 
remains as to whether equally impressive differences would be seen when 
comparing single inhalers containing ICS/LABA/LAMA and LABA/LAMA, 
particularly since LABA/LAMA has been shown to be superior to ICS/LABA 
(5). This will be important to know since combinations containing ICS are 
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more likely to be associated with pneumonia, especially with fluticasone 
furoate which has prolonged lung retention (6). 
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